KR20230119035A - 트레프로스티닐 및 이의 염의 피부 및 경피 투여 - Google Patents

트레프로스티닐 및 이의 염의 피부 및 경피 투여 Download PDF

Info

Publication number
KR20230119035A
KR20230119035A KR1020237026190A KR20237026190A KR20230119035A KR 20230119035 A KR20230119035 A KR 20230119035A KR 1020237026190 A KR1020237026190 A KR 1020237026190A KR 20237026190 A KR20237026190 A KR 20237026190A KR 20230119035 A KR20230119035 A KR 20230119035A
Authority
KR
South Korea
Prior art keywords
drug
treprostinil
patch
skin
transdermal patch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237026190A
Other languages
English (en)
Korean (ko)
Inventor
샤오밍 장
사이러스 케이. 베커
미낙시 에스. 벤카트라만
Original Assignee
코세어 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코세어 파마 인코포레이티드 filed Critical 코세어 파마 인코포레이티드
Publication of KR20230119035A publication Critical patent/KR20230119035A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237026190A 2016-12-05 2017-12-05 트레프로스티닐 및 이의 염의 피부 및 경피 투여 Ceased KR20230119035A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662430053P 2016-12-05 2016-12-05
US62/430,053 2016-12-05
PCT/US2017/064612 WO2018106632A1 (en) 2016-12-05 2017-12-05 Dermal and transdermal administration of treprostinil and salts thereof
KR1020197018666A KR20190109399A (ko) 2016-12-05 2017-12-05 트레프로스티닐 및 이의 염의 피부 및 경피 투여

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018666A Division KR20190109399A (ko) 2016-12-05 2017-12-05 트레프로스티닐 및 이의 염의 피부 및 경피 투여

Publications (1)

Publication Number Publication Date
KR20230119035A true KR20230119035A (ko) 2023-08-14

Family

ID=60782377

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237026190A Ceased KR20230119035A (ko) 2016-12-05 2017-12-05 트레프로스티닐 및 이의 염의 피부 및 경피 투여
KR1020197018666A Ceased KR20190109399A (ko) 2016-12-05 2017-12-05 트레프로스티닐 및 이의 염의 피부 및 경피 투여

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197018666A Ceased KR20190109399A (ko) 2016-12-05 2017-12-05 트레프로스티닐 및 이의 염의 피부 및 경피 투여

Country Status (8)

Country Link
US (1) US20190290597A1 (enExample)
EP (1) EP3548010A1 (enExample)
JP (2) JP2020500882A (enExample)
KR (2) KR20230119035A (enExample)
CN (1) CN110381930A (enExample)
CA (1) CA3045917A1 (enExample)
IL (1) IL267046A (enExample)
WO (1) WO2018106632A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11607026B2 (en) * 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2019218006A1 (en) * 2018-05-14 2019-11-21 Butterworth Building Oil therapy method and device
AU2019344541B2 (en) * 2018-09-18 2022-01-06 Eli Lilly And Company Erbumine salt of treprostinil
US20230293352A1 (en) * 2020-08-16 2023-09-21 Ofer Spottheim Medical dressing
JP2024094445A (ja) * 2021-03-17 2024-07-10 国立大学法人九州大学 経皮吸収剤
EP4313007A4 (en) * 2021-03-31 2025-03-12 Lyfe CHNG, LLC TRANSDERMAL SYSTEM, FORMULATION AND METHOD FOR THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT
CN113842377A (zh) * 2021-08-11 2021-12-28 杭州师范大学 一种经皮递送榄香烯的pdms微针贴片及其制备方法
US20250017870A1 (en) * 2021-11-15 2025-01-16 Artience Co., Ltd. Adhesive patch containing selexipag as active ingredient
WO2023114755A1 (en) * 2021-12-13 2023-06-22 WELSH Stephen Adhesive bandage system for medication delivery and indication of procedure location
WO2023144276A1 (en) * 2022-01-27 2023-08-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of selexipag
JP2025515512A (ja) * 2022-04-29 2025-05-15 兆科薬業（広州）有限公司 トレプロスチニルソフトミスト吸入剤
WO2024015602A1 (en) * 2022-07-15 2024-01-18 Aso Llc Therapeutic foot patch for cough treatment
CN118178292B (zh) * 2024-03-07 2024-10-01 广州博科化妆品有限公司 一种含有水蛭素和植物提取物的防脱洗发露及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4262003A (en) 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
GB9011588D0 (en) * 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US5234690A (en) 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
CA2959852A1 (en) 2003-05-22 2005-01-27 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
WO2005009510A2 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
CN101647792B (zh) * 2003-12-16 2012-11-28 联合治疗公司 曲前列环素在制备治疗和预防缺血性损害的药物中的用途
DE602005020269D1 (de) * 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
CA3084317C (en) * 2008-03-31 2024-01-09 Passport Technologies, Inc. Permeant delivery system and methods for use thereof
US8350079B2 (en) 2008-05-08 2013-01-08 United Therapeutics Corporation Treprostinil formulation
US20110294815A1 (en) 2008-06-27 2011-12-01 Harbeson Scott L Prostacyclin analogs
US9327105B2 (en) * 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
WO2014022376A2 (en) * 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
US9505737B2 (en) * 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
JP2016517410A (ja) 2013-03-14 2016-06-16 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの固体形態
US9394227B1 (en) * 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Also Published As

Publication number Publication date
CA3045917A1 (en) 2018-06-14
KR20190109399A (ko) 2019-09-25
JP2020500882A (ja) 2020-01-16
IL267046A (en) 2019-07-31
CN110381930A (zh) 2019-10-25
EP3548010A1 (en) 2019-10-09
JP2023134620A (ja) 2023-09-27
US20190290597A1 (en) 2019-09-26
WO2018106632A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
JP2023134620A (ja) トレプロスチニルおよびその塩の皮膚投与および経皮投与方法
Akhtar et al. Non-invasive drug delivery technology: Development and current status of transdermal drug delivery devices, techniques and biomedical applications
US5750141A (en) Administration of vaso-active agent and therapeutic agent
Benson et al. Topical and transdermal drug delivery: principles and practice
ES2452517T3 (es) Composiciones y métodos para el tratamiento del trastorno de déficit de atención y del trastorno de déficit de atención e hiperactividad con metilfenidato
AU2009233617B2 (en) Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
Tanner et al. Delivering drugs by the transdermal route: review and comment
Ranade Drug delivery systems. 6. Transdermal drug delivery
AU743516B2 (en) Topical anesthetic formulation
Vitorino et al. Overcoming the skin permeation barrier: challenges and opportunities
JP5487461B2 (ja) 薬物の皮膚送達のための接着性外皮形成製剤とそれを使用する方法
Tiwary et al. Innovations in transdermal drug delivery: formulations and techniques
ES2388355T3 (es) Sistemas de suministro transdémico que comprenden bupivacaína
Williams Topical and transdermal drug delivery
US20070082041A1 (en) Topical delivery of codrugs
US20140314815A1 (en) Adhesive solid gel-forming formulations for dermal drug delivery
JP5563473B2 (ja) マイクロニードル孔バイアビリティを向上させるための方法及び組成物
CN102085198A (zh) 透皮给药系统
Deulkar et al. A review on transdermal drug delivery system
US20250205173A1 (en) Dermal and transdermal administration of treprostinil and salts thereof
Deshwal et al. Optimization techniques in transdermal drug delivery system
JP2007001938A (ja) 微細針付き貼付剤
HK40016649A (en) Dermal and transdermal administration of treprostinil and salts thereof
Pinnamraju et al. A Review on Current Advances in Transdermal Drug Delivery Systems
AU681390B2 (en) Administration of vaso-active agent and therapeutic agent

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230731

Application number text: 1020197018666

Filing date: 20190627

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230911

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240826

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20250124

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20250124

X601 Decision of rejection after re-examination